- €35 million funding round led by international investors
- Key investors include Evonik Venture Capital, BOLD, DeepTech & Climate Fonds, Clay Capital, Icos Capital, and Liberset
- Investment to scale biomanufacturing, accelerate R&D, and expand Microbiome Studio
- New strategic partnership with L’Oréal and Evonik for market innovations in healthcare, cosmetics, and chemicals
Investment Overview
Abolis Biotechnologies has secured €35 million in a financing round led by an international consortium of investors. This funding will support the company's global market expansion and accelerate its research and development efforts in biomanufacturing and microbiome solutions.
Key Investors
The investment round includes contributions from industry leaders such as Evonik Venture Capital and BOLD (L'Oréal's venture capital fund), as well as impact-focused funds like DeepTech & Climate Fonds (Germany), Clay Capital (Singapore), Icos Capital (Netherlands), and the transatlantic investment firm Liberset.
Strategic Goals
The funding will enable Abolis to scale its biomanufacturing operations, develop its own line of products, and expand the activities of Microbiome Studio, a business unit focused on microbial ecosystems. Additionally, the investment will facilitate the recruitment of professionals, particularly for an international Business Development team.
New Partnerships
A new strategic industrial partnership has been signed between Abolis, L’Oréal, and Evonik to bring selected innovations to market in the healthcare, cosmetic, and chemical sectors. This collaboration aims to leverage Abolis' competencies in strain development and metabolic engineering alongside Evonik's expertise in fermentation processes and commercial production.
Future Prospects
Since its establishment in 2014, Abolis Biotechnologies has previously raised €1.1 million and achieved significant growth through strategic partnerships. This new funding round marks a pivotal phase in the company's development, enabling it to expand its manufacturing platforms and better serve its growing customer base.
